“There’s no acceptable cancer risk for a drug like this.”
(David Light, CEO of Valisure)
Zantac Lawsuits | Ranitidine Lawsuits
Ranitidine (brand name: Zantac) is known to form NDMA for decades. However, only after an independent online pharmacy lab tested Zantac in 2019 and warned the FDA about what even the agency called “unacceptable” levels of the carcinogen linked to the drug, did the FDA conduct its own research.
On April 1, 2020, the U.S. Food and Drug Administration announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine (Zantac) drugs from the market immediately
Peiffer Wolf has represented thousands of clients from across the United States in cases related to pharmaceutical products and medical devices. If you have been diagnosed with cancer after taking Zantac regularly, we want to hear from you. Contact Us Today by calling 504-523-2434 or by filling out an online Contact Form for a FREE Consultation.
Zantac Lawsuit | Zantac under investigation
- 1980s: Ranitidine is shown to form NDMA in conditions of the human stomach*
- 2004: National Cancer Institute links ranitidine to bladder cancer*
- 2016: Stanford University professor William Mitch and Syracuse University professor Teng Zeng find NDMA in the urine of 10 volunteers who were given Zantac. The study highlights that the levels of NDMA found are 400 greater than what the FDA considers acceptable.
- June 2019: Routine drug testing performed by online pharmacy Valisure in its labs link Zantac and its generics to a carcinogen chemical, NDMA. Valisure notifies the FDA.
- September 2019: Valisure files a petition with the FDA asking for a recall of all products containing ranitidine.
- September 2019: both the FDA and the European Medicines Agency decide to review Zantac.
- September 2019: GlaxoSmithKline, which sells Zantac outside the US, issues a Generic ranitidine makers in the US – Apotex and Sandoz – issue voluntary recalls as well. Sanofi, which sells Zantac in the US, does not issue recalls.
- September 2019: CVS, Walgreens, Rite Aid and Wal Mart suspend the sales of Zantac/Ranitidine products in the US.
- October 2019: Memorial Sloan Kettering Cancer Center removes Zantac from the list of drugs that it offers to patients.
- October 2019: Sanofi finally announces a select amount of Zantac to be recalled in the US.
- April 2020: The U.S. Food and Drug Administration announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine (Zantac) drugs from the market immediately
* Sources: Valisure and FDA